Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Is disrupting cardiac fibrosis a rational strategy for treating heart disease?

Fibrosis is a common sequela of cardiovascular disease that results in structural and functional changes. Targeting the subsets of pathogenic cardiac fibroblasts may be an attractive option for reducing morbidity that is associated with heart disease, but the timing, specificity and extent to which fibroblast-targeting therapies might be used is still debated.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Potential opportunities for targeting cardiac fibroblasts.


  1. Tallquist, M. D. et al. Nat. Rev. Cardiol. 14, 484–491 (2017).

    Article  Google Scholar 

  2. Plikus, M. V. et al. Cell 184, 3852–3872 (2021).

    CAS  Article  Google Scholar 

  3. Bowers, S. L. K. et al. Nat. Cardiovasc. Res. 1, 312–321 (2022).

    Article  Google Scholar 

  4. Muhl, L. et al. Nat. Commun. 11, 3953 (2020).

    CAS  Article  Google Scholar 

  5. Fu, X. et al. J. Clin. Invest. 128, 2127–2143 (2018).

    Article  Google Scholar 

  6. Farbehi, N. et al. eLife 8, e43882 (2019).

    Article  Google Scholar 

  7. Forte, E. et al. Cell Rep. 30, 3149–3163.e6 (2020).

    CAS  Article  Google Scholar 

  8. Peyser, R. et al. Am. J. Resp. Cell Mol. 61, 74–85 (2019).

    CAS  Article  Google Scholar 

  9. Kanisicak, O. et al. Nat. Commun. 7, 12260 (2016).

    CAS  Article  Google Scholar 

  10. Aghajanian, H. et al. Nature 573, 430–433 (2019).

    CAS  Article  Google Scholar 

  11. Drago, J. Z. et al. Nat. Rev. Clin. Oncol. 18, 327–344 (2021).

    Article  Google Scholar 

  12. Sheppard, D. Ann. Am. Thorac. Soc. 12, S21–S23 (2015).

    Article  Google Scholar 

  13. Frangogiannis, N. G. Nat. Rev. Cardiol. (2022).

  14. Schafer, S. et al. Nature 552, 110–115 (2017).

    CAS  Article  Google Scholar 

  15. López, B. et al. Nat. Rev. Cardiol. 18, 479–498 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations



Both authors prepared the Comment.

Corresponding author

Correspondence to Michelle D. Tallquist.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hara, A., Tallquist, M.D. Is disrupting cardiac fibrosis a rational strategy for treating heart disease?. Nat Cardiovasc Res 1, 405–407 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing